Market Overview

Stifel Nicolaus Reinstates Hold on Acorda Therapeutics, Lowers Price Target to $25


This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for ACOR

Aug 2018Cantor FitzgeraldInitiates Coverage OnNeutral
Aug 2018Stifel NicolausMaintainsHoldHold
Jan 2018OppenheimerMaintainsPerformPerform

View More Analyst Ratings for ACOR
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings


Related Articles (ACOR)

AT&T, Disney, Pfizer, Wynn Resorts: 'Fast Money' Picks For August 7

Mike Khouw Sees Unusual Options Activity In Sprint